CochLear (CHEOY) Stock Price, News & Analysis

Company Overview

Cochlear Limited is an Australian medical device company that develops, manufactures and supplies implantable hearing solutions for people with moderate to profound hearing loss. Its portfolio includes cochlear implants, bone conduction implants and related sound processors, accessories and connectivity products designed to help users hear in a range of environments.

The company also provides clinical support, rehabilitation resources, software, technical services and ongoing care for recipients, clinicians and hearing professionals. Cochlear serves customers through a global network spanning Australia, the Americas, Europe, Asia and other international markets.

Cochlear traces its origins to research led by Australian scientist Graeme Clark and the development of the modern multi-channel cochlear implant. The company was established in the 1980s and is headquartered in Sydney, Australia. Its operations include research and development, manufacturing, sales and recipient-support activities, with products distributed in numerous countries worldwide.

Key Stats

• Today's Range: $50.01 to $50.40
• 50-Day Range: $43.58 to $51.41
• 52-Week Range: $31.82 to $98.29
• Volume: 5,662 shs
• Average Volume: 47,428 shs
• Market Capitalization: $6.59 billion
• P/E Ratio: N/A
• Dividend Yield: 1.51%
• Price Target: $117.00
• Consensus Rating: Hold

CochLear Stock Analysis - MarketRank™

CochLear scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

CochLear has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 5 hold ratings, and no sell ratings.

Upside Potential

CochLear has a consensus price target of $117.00, representing about 132.2% upside from its current price of $50.40.

Amount of Analyst Coverage

CochLear has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 10.36%

Earnings Growth

Earnings for CochLear are expected to grow by 10.36% in the coming year, from $1.93 to $2.13 per share.

Price to Book Value per Share Ratio

CochLear has a P/B Ratio of 5.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of CochLear has been sold short.

Short Interest Ratio / Days to Cover

CochLear has a short interest ratio ("days to cover") of 0.02, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CochLear has recently increased by 9.43%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

CochLear pays a meaningful dividend of 1.55%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

CochLear does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, CochLear will have a dividend payout ratio of 35.68% next year. This indicates that CochLear will be able to sustain or increase its dividend.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for CochLear this week, compared to 1 article on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CochLear insiders have not sold or bought any company stock.

Percentage Held by Institutions

CochLear has minimal institutional ownership at this time.

Company Calendar

• Today: 11/04/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:CHEOY
• Previous Symbol: OTCMKTS:CHEOY
• CIK: 1453930
• Web: www.cochlear.com
• Phone: (129) 428-6555
• Fax: N/A
• Employees: 5,400
• Year Founded: 1982

Price Target and Rating

• Average Price Target for CochLear: $117.00
• High Price Target: $117.00
• Low Price Target: $117.00
• Potential Upside/Downside: +132.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.15
• Quick Ratio: 1.34

Sales & Book Value

• Annual Sales: $1.59 billion
• Price / Sales: 4.14
• Cash Flow: $2.27 per share
• Price / Cash Flow: 22.18
• Book Value: $9.03 per share
• Price / Book: 5.58

Miscellaneous

• Outstanding Shares: 130,800,000
• Free Float: N/A
• Market Cap: $6.59 billion
• Optionable: Not Optionable
• Beta: 0.69